Aimmune plans to declare results of Phase 3 PALISADE Trial of AR101 for Peanut Allergy

Aimmune Therapeutics announced its plans for the upcoming year to report top-line results in February from a pivotal phase 3 PALISADE trial of AR101 for peanut allergy following the completion of the 554-subject trial in late 2017Aimmune who is into developing cures for food allergies wishes to desensitize peanut allergy patients with AR101.

Aimmune CEO Stephen Dilly, M.B.B.S., Ph.D. “Thanks to the dedication of our employees, investigators, and patients, we accomplished what we laid out at the beginning of 2017 — the completion of PALISADE, the opening and qualification of our commercial manufacturing facility, and the initiation of our additional AR101 Phase 3 studies amidst high patient demand that exceeded our projections. We also saw further confirmation of our position as a partner of choice, as we formed a clinical collaboration with Regeneron and Sanofi to study AR101 treatment with adjunctive dupilumab, and we continued to benefit from our important relationships with Nestlé Health Science and Golden Peanut and Tree Nuts.